Meeting
2023 ASCO Annual Meeting
Trends in diagnosis of de novo metastatic hormone sensitive prostate cancer in US Veterans, 2002-2021.
Authors
Nada Al masalmeh
St. Louis University, St. Louis, MO
Nada Al masalmeh , Ruth Douglas Etzioni , Saira Khan , Arslan Babar , Kristen Marie Sanfilippo , Robert Bruce Montgomery , Eric Marshall Knoche , Lukas Owens , Yu-Ning Wong , Martin W. Schoen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Etiology/Epidemiology
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10527)
DOI
10.1200/JCO.2023.41.16_suppl.10527
Abstract #
10527
Poster Bd #
160
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Association of multiparametric magnetic resonance imaging findings with oncologic outcomes in non-palpable localized prostate cancer.
First Author: Abhishek Kumar
Poster
2023 ASCO Annual Meeting
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle F Burgess
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of COVID-19 on the incidence of prostate cancer among White and Black Veterans.
First Author: Kyung Min Lee
Poster
2020 Genitourinary Cancers Symposium
Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).
First Author: Lauren Christine Harshman